Mumbai, September 21, 2013: The Indian pharmaceutical industry currently tops the chart amongst India’s science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organized sector, the Indian pharmaceutical industry is estimated to be worth $ 23 billion; both domestic and export, growing at about 14 to 15 percent annually. Taking the leadership and expertise of connecting the pharma businesses through CPhI and P-MEC India, which is South Asia’s largest and most comprehensive event for the pharmaceutical industry, to the next level, UBM India is set to honour path breaking excellence, by hosting the press conference on “Awarding Excellence in the Pharmaceutical Industry” to announce the launch of UBM India Pharma Awards on 17th of September 2013 at the Cowasjee Jehangir, ITC Grand Central, Parel, Mumbai. The press conference will be followed by the unveiling of the trophy for the UBM India Pharma Awards. The conference was presided over by Mr. Ajit Singh, Chairman, ACG- Worldwide; Shri. Mural Nair, Partner- Ernst & Young, and Mr. Joji George, Managing Director- UBM India.
According to Mr. Joji George, “UBM India believes that these initiatives are required to pave the way for stable growth, provide universal health benefits, social and environmental safety, resulting ultimately in enhancing the global image of the Indian Pharmaceutical industry. “
The press conference will provide details on how the India Pharma Awards will honour companies who have excelled in Pharmaceuticals and who have contributed to the growth and development of the Indian industry and overall economy. UBM India on 2nd December, 2013 through this award ceremony will recognize and reward select, path-breaking initiatives undertaken by the Indian Pharmaceutical industry around key areas of quality, product design, cost management, packaging, corporate social responsibility, research & development. The press conference will also specify the categories for the awards and the jury members for the same.
The event was also graced by the honourable jury of the UBM India Pharma Awards, including Dr. Ajit Dangi, President and CEO, Danssen Consulting; Mr. Devinder Pal, President, Catalyst Pharma Consult; Mr. Murali Nair, Partner Ernst & Young; Shri. Kaushik Desai, Director, Drug Information Association (DIA).
The Indian Pharmaceutical sector has more than 10,000 registered units. The pharmaceutical industry in India meets around 70% of the country’s demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectibles. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously. There are about 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units). These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 500 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulations.
With India now the hub for high quality, affordable pharma solutions, India Pharma Awards by UBM India will give an opportunity to companies to engage with the movers and shakers in India’s pharma machinery, technology, ingredients, outsourcing and biopharma industry. There is a constant growth taking place in the pharmaceutical industry today and UBM India plans to take this growth ahead to the next level by launch of the Indian Pharma Awards. — CCI Newswire
